gabexate has been researched along with Nephrosis, Lipoid in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Nephrosis, Lipoid: A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsubara, M | 1 |
| Nogae, S | 1 |
| Ito, S | 1 |
1 other study available for gabexate and Nephrosis, Lipoid
| Article | Year |
|---|---|
Novel trial for the treatment of steroid dependency in minimal change disease: combined therapy of camostat mesilate and glycyrrhizin.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Th | 2002 |